Executive Director, Product Strategy and Valuation

BeiGene, Ltd. has proposed to change its name to BeOne Medicines Ltd. The new name is subject to shareholder approval and, once approved, use of the name will be phased in over 2025. There may be instances where “BeiGene” or “BeOne” are used to describe the company during this transition period. BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.

The Executive Director, Product Strategy and Valuation position will lead a team of approximately six individuals and be part of the GCSO Leadership Team. This role will be responsible for guiding the team to build commercial and business case assessments for both business development opportunities and internal pipeline programs and for playing a leadership role at BeOne Portfolio Review Committee (BPRC). This role will also assist with/leading certain ad-hoc cross-functional initiatives.   

Essential Functions & Responsibilities: 

Primary responsibilities include but are not limited to: 

• Lead pipeline commercial assessment across all therapeutic areas and development stages for enterprise planning and annual LRP purposes  

• Support commercial assessments through appropriate insight generation and subsequent quantification of the opportunity, with clear articulation of key assumptions / value drivers / risk parameters 

• Engage with key stakeholders across R&D and commercial teams to ensure visibility of key assumptions and resulting project-related forecasts.  Develop strong working relationships with key partners such as Pricing/Access, GCSO franchise teams, CBDI and GPPM to ensure cross-functional perspectives are incorporated within commercial assessments 

• Develop portfolio-level view of BeOne pipeline to ensure thorough understanding of the impact upon commercial assessments arising from overlapping development plans, or through cannibalization of later lines of therapy as asset LCM plans move into earlier treatment settings  

• Drive quantitative and support qualitative commercial input at both the indication and program levels to inform portfolio prioritization; collaborate with GPPM to develop informative and effective multidisciplinary portfolio prioritization framework and process 

• Support the commercial and business case assessments for major pipeline investment decisions at the BPRC level and to inform go-no-go decisions at DRC, ERC, and program team (i.e. GPT, DCT, EDT, BU) levels, working cross functionally with R&D and GCSO team members 

•  Partner with both global commercial franchise teams and BD to support commercial assessment for global business development a ctivities, covering all deal types and targets/assets at all development stages 

•  Inform and influence TPP/CDP development, Disease Area Strategies and asset-level strategy formulation by synthesizing insights from primary market research, treatment/competitive landscape monitoring and commercial assessment-based analytics   

• Manage budget, AOP and LRP for the full team